报价延迟最少15分钟:2025/11/16 08:43 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.03 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.24/-1.12
|
|
企业价值
15.70M
|
| 资产负债 |
|
每股账面净值
0.39
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.15
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/11/16 08:43 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). |
